Results 141 to 150 of about 241,196 (260)

Advances in Immune-Based Approaches for the Cure of HIV Infection. [PDF]

Drugs
Wagner JA, Sandel DA, Deitchman AN, Rutishauser RL, Deeks SG, Peluso MJ.   +5 more
europepmc   +1 more source

Untangling CSR Decoupling: Board Attributes Effects and the Unexplored Moderating Role of Board Gender Diversity

Business Ethics, the Environment &Responsibility, EarlyView.
ABSTRACT This study investigates the phenomenon of corporate social responsibility (CSR) decoupling, wherein firms' CSR disclosures diverge from their actual CSR performance, often resulting in misleading portrayals of environmental and social commitments commonly associated with greenwashing.
María Consuelo Pucheta‐Martínez, Isabel Gallego‐Álvarez, Inmaculada Bel‐Oms   +2 more
wiley   +1 more source

Daily pill can prevent HIV : reaching people who could benefit from PrEP

Preexposure prophylaxis (PrEP) is a medicine taken daily that can be used to prevent getting HIV. PrEP is for people without HIV who are at very high risk for getting it from sex or injection drug use.

core  

Use of dual ART in individuals with different HBV serological patterns. [PDF]

Curr Opin HIV AIDS
Swaine T, Bhagani S.
europepmc   +1 more source

An Evaluation of Foreign Clinical Data in the Approval Reviews of Antimicrobial Medicines in Japan: Considering Ethnic and Regional Differences in Data Extrapolations in Accordance With Regulatory Circumstances. [PDF]

Pharmacol Res Perspect
Shimazawa R, Ikeda M.
europepmc   +1 more source

Cancer pain: current practice and emerging targets

British Journal of Pharmacology, EarlyView.
Cancer pain (CP) arises from a complex interplay between the tumour and its microenvironment. Many patients experience a mixed pain phenotype that encompasses nociceptive, neuropathic and neuroinflammatory mechanisms, and vary across tumour type and disease stage. Despite decades of intensive research, the mainstay of cancer pain treatment is still non‐
Yi Ye, Marcin Chwistek, Zhiting Gong, Vanessa Uzonwanne, Xiaojie Shi, Arpad Szallasi   +5 more
wiley   +1 more source

Status of Human Immunodeficiency Virus Testing, Viral Suppression, and HIV Preexposure Prophylaxis \u2014 United States, 2013\u20132018

Background: Approximately 38,000 new human immunodeficiency Virus (HIV) infections occur in the United States each year; these infections can be prevented.

core  

Natural Products as Anti-HIV Agents and Role in HIV-Associated Neurocognitive Disorders (HAND): A Brief Overview. [PDF]

Front Microbiol, 2015
Kurapati KR, Atluri VS, Samikkannu T, Garcia G, Nair MP.   +4 more
europepmc   +1 more source

Identification, reliability, and validity of drug–drug interaction checkers in chronic diseases: A systematic review

British Journal of Pharmacology, EarlyView.
Abstract Drug–drug interactions (DDIs) pose major risks in chronic disease management where polypharmacy is common. Although digital DDI tools are used widely to aid healthcare professionals, tools rely on theoretical interactions. This limitation questions their reliability and validity for clinical relevancy.
Brayden Ng Gibson, Sri Chodapuneedi, Huan Yee Koh, Sugandha Gupta, Danijela Gasevic, Anna Yuanyuan Wang, Catia Marzolini, Saye Khoo, Lorena Romero, Lachlan Dalli, Jack Janetzki, Harvey Jia Wei Koh, Stella Talic   +12 more
wiley   +1 more source

Preexposure prophylaxis for the prevention of HIV infection in the United States \u2013 2021 update clinical providers\u2019 supplement

The Preexposure Prophylaxis for the Prevention of HIV Infection in the United States \u2013 2014 Clinical Providers\u2019 Supplement was published in an electronic format in July 2014 so that it could be updated as relevant changes in supporting evidence

core